Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
GlyProVac logo — Exploring novel bacterial glycopeptide antigens to address u...

GlyProVac

Exploring novel bacterial glycopeptide antigens to address unmet needs in vaccine development

Founded 2018 Denmark Denmark 11 employees Grant Total: $467.00K Biopharma

General Information

Company Name GlyProVac
Founded Year 2018
Location Denmark Denmark +1
Employees 11
Industries Biopharma
Funding Stage Grant
Social

Get notified when GlyProVac moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About GlyProVac

GlyProVac LLC is a biopharma startup based in Denmark, founded in 2018. The company focuses on exploring novel bacterial glycopeptide antigens to address unmet needs in vaccine development. Their proprietary platform technology, BEMAP, has led to the discovery that O-linked protein glycosylation is abundant in bacteria, and glycoproteins are linked to increased immunogenicity. GlyProVac aims to be the first to explore and exploit this novel class of antigens for vaccine development. Their lead candidate, YghJ/SslE/AcfD, has shown vaccine potential not only in ETEC but also in UPEC. Utilizing BEMAP, GlyProVac has identified 59 glycosylated residues in YghJ. The company is currently in the proof-of-concept phase, working to establish that glycosylated YghJ elicits a more protective immune response compared to the non-glycosylated version. Their most recent investment of $467.00K in the form of a grant investment came on 29 February 2024 from CARB-X. With a focus on leveraging innovative technology to advance vaccine development, GlyProVac presents an intriguing investment opportunity in the biopharma sector.

Taxonomy: Vaccine Development, Bacterial Glycopeptide Antigens, BEMAP Technology, Protein Glycosylation, Immunogenicity, YghJ/SslE/AcfD Protein, Enterotoxigenic Escherichia coli (ETEC), PoC Phase, Mass Spectrometry, Microbiology, Molecular Biology, Bacterial Pathogens

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
29 Feb 2024

GlyProVac Alternatives & Competitors

GlyProVac vs
Recbio
Recbio China

Protect Human Health with Best-in-class Vaccines

Series C
21 employees
Health Care, Life Sciences
GlyProVac vs
Vectron Biosolutions AS
Vectron Biosolutions AS

Unique solutions to unique problems

Series A
11 employees
Biotechnology, Health Care
GlyProVac vs
Scarab Genomics
Scarab Genomics

High-Efficiency Production of Proteins & Nucleic Acids in Clean Genome® E.coli hosts

12 employees
Biotechnology, Health Care

FAQ About GlyProVac

Exploring novel bacterial glycopeptide antigens to address unmet needs in vaccine development
GlyProVac was founded in 2018.
GlyProVac is headquartered in Denmark.
GlyProVac operates in the following industries: Biopharma.
GlyProVac has approximately 11 employees.
GlyProVac has completed 1 funding round, raising a total of $467.00K. The latest funding stage is Grant.
Top alternatives and competitors to GlyProVac include Recbio, Vectron Biosolutions AS, Scarab Genomics, MarraBio, ENGIMATA INC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
GlyProVac and Recbio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors GlyProVac and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy